Mammography screening is one of the most widely deployed tools for early breast cancer detection and has been shown to decrease mortality in multiple randomized clinical trials.
1 However, screening mammography is imperfect with 1 in 8 cancers missed at time of interpretation in US community practice.
2 Roughly 9% to 10% of the 40 million US women who undergo routine breast screening each year are recalled for additional diagnostic imaging; only 4% to 5% of women recalled are ultimately diagnosed as having breast cancer.
2 These false positives lead to preventable harms, included patient anxiety, benign biopsies, and unnecessary intervention or treatment.
3 High false-positive rates incur significant resources and contribute to the annual $10 billion mammography screening costs in the United States.
4